Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial
It has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of <i>L. paracasei<...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Foods |
Subjects: | |
Online Access: | https://www.mdpi.com/2304-8158/10/7/1455 |
id |
doaj-b0b89dedd45c4a2e843f261e61e0b6f5 |
---|---|
record_format |
Article |
spelling |
doaj-b0b89dedd45c4a2e843f261e61e0b6f52021-07-23T13:40:10ZengMDPI AGFoods2304-81582021-06-01101455145510.3390/foods10071455Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical TrialParichart Toejing0Nanticha Khampithum1Sasithorn Sirilun2Chaiyavat Chaiyasut3Narissara Lailerd4Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandInnovation Center for Holistic Health, Nutraceuticals and Cosmeceuticals, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, ThailandDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandIt has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of <i>L. paracasei</i> HII01 on glycemia in T2DM patients. In a randomized, double-blind, placebo-controlled study, 50 participants were allocated to receive <i>L. paracasei</i> HII01 (50 × 10<sup>9</sup> CFU/day) or a placebo (corn starch 10 mg/day). Blood and fecal samples were assessed at baseline and at the end of the trial. After 12 weeks of intervention, fasting blood glucose level had significantly decreased in the probiotic group compared with the placebo group. Importantly, probiotic supplementation significantly decreased the plasma levels of LPS, TNF-α, IL-6 and hsCRP compared the placebo group. Additionally, an increase in beneficial bacteria and a decrease in pathogenic bacteria, which related to the improvement of SCFAs, was found following <i>L. paracasei</i> HII01 supplementation. These findings demonstrated that <i>L. paracasei</i> HII01 improved hyperglycemia and inflammatory markers by favorably modifying gut microbiota and subsequently ameliorating the leaky gut and endotoxemia, thereby suggesting a potential role as an adjuvant treatment in type 2 diabetes.https://www.mdpi.com/2304-8158/10/7/1455<i>Lactobacillus paracasei</i>probioticstype 2 diabetes mellitusgut microbiotaglycemiainflammation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Parichart Toejing Nanticha Khampithum Sasithorn Sirilun Chaiyavat Chaiyasut Narissara Lailerd |
spellingShingle |
Parichart Toejing Nanticha Khampithum Sasithorn Sirilun Chaiyavat Chaiyasut Narissara Lailerd Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial Foods <i>Lactobacillus paracasei</i> probiotics type 2 diabetes mellitus gut microbiota glycemia inflammation |
author_facet |
Parichart Toejing Nanticha Khampithum Sasithorn Sirilun Chaiyavat Chaiyasut Narissara Lailerd |
author_sort |
Parichart Toejing |
title |
Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial |
title_short |
Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial |
title_full |
Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial |
title_fullStr |
Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial |
title_full_unstemmed |
Influence of <i>Lactobacillus paracasei</i> HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial |
title_sort |
influence of <i>lactobacillus paracasei</i> hii01 supplementation on glycemia and inflammatory biomarkers in type 2 diabetes: a randomized clinical trial |
publisher |
MDPI AG |
series |
Foods |
issn |
2304-8158 |
publishDate |
2021-06-01 |
description |
It has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of <i>L. paracasei</i> HII01 on glycemia in T2DM patients. In a randomized, double-blind, placebo-controlled study, 50 participants were allocated to receive <i>L. paracasei</i> HII01 (50 × 10<sup>9</sup> CFU/day) or a placebo (corn starch 10 mg/day). Blood and fecal samples were assessed at baseline and at the end of the trial. After 12 weeks of intervention, fasting blood glucose level had significantly decreased in the probiotic group compared with the placebo group. Importantly, probiotic supplementation significantly decreased the plasma levels of LPS, TNF-α, IL-6 and hsCRP compared the placebo group. Additionally, an increase in beneficial bacteria and a decrease in pathogenic bacteria, which related to the improvement of SCFAs, was found following <i>L. paracasei</i> HII01 supplementation. These findings demonstrated that <i>L. paracasei</i> HII01 improved hyperglycemia and inflammatory markers by favorably modifying gut microbiota and subsequently ameliorating the leaky gut and endotoxemia, thereby suggesting a potential role as an adjuvant treatment in type 2 diabetes. |
topic |
<i>Lactobacillus paracasei</i> probiotics type 2 diabetes mellitus gut microbiota glycemia inflammation |
url |
https://www.mdpi.com/2304-8158/10/7/1455 |
work_keys_str_mv |
AT paricharttoejing influenceofilactobacillusparacaseiihii01supplementationonglycemiaandinflammatorybiomarkersintype2diabetesarandomizedclinicaltrial AT nantichakhampithum influenceofilactobacillusparacaseiihii01supplementationonglycemiaandinflammatorybiomarkersintype2diabetesarandomizedclinicaltrial AT sasithornsirilun influenceofilactobacillusparacaseiihii01supplementationonglycemiaandinflammatorybiomarkersintype2diabetesarandomizedclinicaltrial AT chaiyavatchaiyasut influenceofilactobacillusparacaseiihii01supplementationonglycemiaandinflammatorybiomarkersintype2diabetesarandomizedclinicaltrial AT narissaralailerd influenceofilactobacillusparacaseiihii01supplementationonglycemiaandinflammatorybiomarkersintype2diabetesarandomizedclinicaltrial |
_version_ |
1721288496454303744 |